151 related articles for article (PubMed ID: 36694106)
21. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.
Kadota K; Nitadori J; Woo KM; Sima CS; Finley DJ; Rusch VW; Adusumilli PS; Travis WD
J Thorac Oncol; 2014 Aug; 9(8):1126-39. PubMed ID: 24942260
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression.
Kim HS; Kim JK; Lee JH; Lee YJ; Lee GK; Han JY
JCO Precis Oncol; 2024 Apr; 8():e2300495. PubMed ID: 38635931
[TBL] [Abstract][Full Text] [Related]
23. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.
Kotake M; Imai H; Kaira K; Endoh H; Yamada Y; Kaburagi T; Kiyoshima M; Sugiyama T; Nakamura Y; Kasai T; Matsuguma H; Minemura H; Kanazawa K; Suzuki H; Fujita A; Minato K
Chemotherapy; 2022; 67(3):142-151. PubMed ID: 35313303
[TBL] [Abstract][Full Text] [Related]
25. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
26. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of perioperative chemotherapy for pulmonary high-grade neuroendocrine carcinomas: a propensity score matching analysis.
Ogawa H; Tanaka Y; Kitamura Y; Shimizu N; Doi T; Hokka D; Tane S; Nishio W; Yoshimura M; Maniwa Y
J Thorac Dis; 2019 Apr; 11(4):1145-1154. PubMed ID: 31179056
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of Twist, Snail and E-cadherin expression in pathological N0 non-small-cell lung cancer: a retrospective cohort study.
Wang G; Ma W; Li Y; Jiang Y; Ma G; Zhang X; Meng L; Du J
Eur J Cardiothorac Surg; 2018 Aug; 54(2):237-245. PubMed ID: 29415155
[TBL] [Abstract][Full Text] [Related]
29. The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma.
He X; Zhou T; Yang G; Fang W; Li Z; Zhan J; Zhao Y; Cheng Z; Huang Y; Zhao H; Zhang L
Oncotarget; 2016 Mar; 7(12):15274-87. PubMed ID: 26933815
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of heterogeneous ribonucleoprotein A1 expression and inflammatory indicators for patients with surgically resected hepatocellular carcinoma: Perspectives from a high occurrence area of hepatocellular carcinoma in China.
Ke R; Lv L; Li J; Zhang X; Yang F; Zhang K; Jiang Y
Oncol Lett; 2018 Sep; 16(3):3746-3756. PubMed ID: 30127985
[TBL] [Abstract][Full Text] [Related]
31. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
Qin J; Xie F; Li C; Han N; Lu H
Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
[No Abstract] [Full Text] [Related]
32. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
[TBL] [Abstract][Full Text] [Related]
33. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
34. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung.
Ryuge S; Sato Y; Jiang SX; Wang G; Matsumoto T; Katono K; Inoue H; Iyoda A; Satoh Y; Yoshimura H; Masuda N
Lung Cancer; 2012 Aug; 77(2):415-20. PubMed ID: 22572237
[TBL] [Abstract][Full Text] [Related]
37. Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance.
Sun K; Li M; Shang M; Su X; Zhao J; Wang B; Wu C; Zhang L; Yang S; Sun X
Lung Cancer; 2022 Apr; 166():63-69. PubMed ID: 35196635
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
40. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
